Psilocin

Psilocin

SCHEMBL194899

CN(C)CCc1c[nH]c2cccc(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 13/20 1.00
HTR2C P28335 10/20 1.00
HTR2B P41595 9/20 1.00
HTR1A P08908 6/20 1.00
HTR6 P50406 2/20 1.00
DRD1 P21728 1/20 1.00
HTR1D P28221 1/20 1.00
HTR1B P28222 1/20 1.00
HTR1E P28566 1/20 1.00
ADORA2A P29274 1/20 1.00
ADORA2B P29275 1/20 1.00
HTR7 P34969 1/20 1.00
DRD3 P35462 1/20 1.00
HTR5A P47898 1/20 1.00
SLC6A4 P31645 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Psilocin SCHEMBL27221707 1.00 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR6
Psilocin SCHEMBL29363508 1.00 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR6
Psilocin SCHEMBL31188168 1.00 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR6
Psilocin SCHEMBL27169386 1.00 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR6
Psilocin SCHEMBL25193368 0.98 HTR2A (0.97) HTR2AHTR2CHTR2BHTR1AHTR6
Psilocin SCHEMBL26646472 0.94 HTR2A (0.89) HTR2AHTR2CHTR2BHTR1AHTR6
Psilocin SCHEMBL25174340 0.93 HTR2A (0.86) HTR2AHTR2CHTR2BHTR1AHTR6
Psilocin SCHEMBL2761560 0.93 HTR2A (0.86) HTR2AHTR2CHTR2BHTR1AHTR6
Psilocin SCHEMBL25184570 0.93 HTR2A (0.86) HTR2AHTR2CHTR2BHTR1AHTR6
Psilocin SCHEMBL30785664 0.93 HTR2A (0.86) HTR2AHTR2CHTR2BHTR1AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4016 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144807-A1 METHOD OF ADMINISTRATION OF A PARENTERAL FORMULATION COMPRISING A PSYCHEDELIC AGENT CYBIN UK LTD (GB) 2026-05-28 US claimed
US-20260137652-A1 Composition Comprising Non-Phosphorylated Tryptamine SINTALICA S R L (IT) 2026-05-21 US claimed
EP-4172145-B1 TRYPTAMINE PRODRUGS AS SEROTONIN RECEPTOR ACTIVATORS FOR THE TREATMENT OF E.G. DEPRESSION REUNION NEUROSCIENCE INC (US) 2026-05-13 EP claimed
EP-4734978-A2 COMBINATION THERAPIES USING PSILOCYBIN University of Padova (IT) 2026-05-06 EP claimed
US-12616706-B2 Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations Arbormentis LLC (US) 2026-05-05 US claimed
US-20260108493-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND CAAMTECH, INC. (US) 2026-04-23 US claimed
US-20260108544-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2026-04-23 US claimed
US-12595497-B2 Processes for the production of tryptamines COMPASS PATHFINDER LIMITED (GB) 2026-04-07 US claimed
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO LLC (US) 2026-04-02 US claimed
US-20260090957-A1 Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness DRESDNER JR KARL P (US) 2026-04-02 US claimed
WO-2005039546-A2 USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES VEIJLEN N.V. (AN) 2005-05-06 WO claimed
WO-2004111185-A2 DIRECT MICRO-PATTERNING OF LIPID BILAYERS USING UV LIGHT AND SELECTED USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-12-23 WO claimed
EP-1474126-A2 TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2004-11-10 EP claimed
US-20040180147-A1 Direct micro-patterning of lipid bilayers using UV light and selected uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-09-16 US claimed
US-20040105881-A1 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin IDEA AG (DE) 2004-06-03 US claimed
WO-2004032900-A1 AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN IDEA AG (DE) 2004-04-22 WO claimed
WO-2003068147-A2 TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER’S DISEASE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2003-08-21 WO claimed
WO-2003016903-A2 DEVICE AND METHOD FOR DETERMINING AN ANALYTE PILS WALTER (AT) 2003-02-27 WO claimed
US-6306616-B1 SAMPLES GIVING POSITIVE REACTION IN DIRECT ASSAY TEST ARE TREATED WITH NEUTRALIZING ANTIBODY THAT INHIBITS REACTIVITY OF TRUE ANALYTE, BUT NOT INTERFERING SUBSTANCE MICROGENICS CORPORATION 2001-10-23 US claimed
EP-0152379-A2 Process for preparing pharmaceutical compositions containing unilamellar liposomes CIBA-GEIGY AG (CH) 1985-08-21 EP claimed